Hikma Pharmaceuticals PLC HIK shares slipped 1.68% to £19.86 Monday, on what proved to be an all-around rough trading session ...

Hikma Pharmaceuticals PLC closed 11.86% below its 52-week high of £23.60, which the company reached on February 13th.

Hikma Pharmaceuticals (HKMPF) announces the approval of KLOXXADO Nasal Spray 8 mg, by Health Canada for the treatment of known or suspected ...

In a report released yesterday, Victoria Lambert from Berenberg Bank maintained a Buy rating on Hikma Pharmaceuticals (HIK – Research Report), with a price target of p2,560.00. The company’s shares ...

LONDON and GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Hikma Pharmaceuticals PLC (Hikma, Group), the multinational generic pharmaceutical company, announces the approval of KLOXXADO ...

Cisatracurium besylate injection has a market value of approximately $14 million in the 12 months ending January 2025, per ...

Revenue: US$3.13b (up 8.8% from FY 2023). Net income: US$359.0m (up 89% from FY 2023). Profit margin: 12% (up from 6.6% in FY 2023). The increase in margin was driven by higher revenue. EPS: US$1. ...

Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada LONDON and GAITHERSBURG, Md., March 20, 2025 (GLOBE ...

Hikma is introducing mercaptopurine oral suspension, in a 20mg/ml dose, which is the first generic of this product. Hikma was the first approved applicant with a Competitive Generic Therapy ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...